Novel findings in drug-induced dendritic cell tolerogenicity

International Reviews of Immunology

Volumn 29, Issue 6, 2010, Pages 574-607

  Švajger, Urban ^a,b   Obermajer, Nataša ^b   Jeras, Matjaž ^a,c  

^a BLOOD TRANSFUSION CENTRE OF SLOVENIA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c Celica Biomedical Sciences Center   (Slovenia)

Author keywords

differentiation; immunosuppressants; maturation; tolerogenic dendritic cells

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; B7 ANTIGEN; CAPSAICIN; CATECHIN; CD86 ANTIGEN; CILOMILAST; CURCUMIN; CYCLOSPORIN A; DEXAMETHASONE; GIVINOSTAT; GLUCOCORTICOID; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; LF 150195; PARTHENOLIDE; RESVERATROL; ROLIPRAM; ROSMARINIC ACID; SINOMENINE; TACROLIMUS; TERIFLUNOMIDE; THROMBOPOIETIN; TRIPTOLIDE; TRITERPENE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VORINOSTAT;

ACETYLATION; ALLERGIC ENCEPHALOMYELITIS; ALLOGENIC BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CLONAL ANERGY; CURCUMA LONGA; CYTOKINE PRODUCTION; CYTOPLASM; DEACETYLATION; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DOWN REGULATION; DRUG INDUCED DISEASE; GENETIC ENGINEERING; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SINOMENIUM; TANACETUM PARTHENIUM; TH1 CELL; TH2 CELL; TRIPTERYGIUM;

ANIMALS; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; CYCLIC AMP; DENDRITIC CELLS; DRUG DISCOVERY; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; NF-KAPPA B; PPAR GAMMA; PURINERGIC P1 RECEPTOR AGONISTS; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION;

EID: 78649294871     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2010.522280     Document Type: Review

References (196)

1. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
2. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unre-sponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769-779.
3. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: Cytokine modulation comes ofage. Blood 2006;108:1435-1440.
4. Mittal R, Prasadarao NV. Outer membrane protein A expression in Escherichia coli K1 is required to prevent the maturation of myeloid dendritic cells and the induction ofIL-10 and TGF-beta. J Immunol 2008;181:2672-2682.
5. Xia CQ, Peng R, Beato F, Clare-Salzler MJ. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand J Im-munol 2005;62:45-54.
6. Hagihara M, Higuchi A, Tamura N, et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol 2004;172:5297-5303.
7. AndersonAE, Swan DJ, Sayers BL, et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol 2009;85:243-250.
8. Brenk M, Scheler M, Koch S, et al. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25 +Foxp3+ T regulatory cells. J Immunol 2009;183:145-154.
9. Manavalan JS, Rossi PC, Vlad G, et al. High expression of ILT3 and ILT4 is a general feature oftolerogenic dendritic cells. Transpl Immunol 2003;11:245-258.
10. Peng Y, Latchman Y, Elkon KB. Ly6C(low) monocytes differentiate into dendritic cells and cross-tolerize T cells through PDL-1. J Immunol 2009;182:2777-2785.
11. Pangault C, Le Friec G, Caulet-Maugendre S, et al. Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Hum Immunol 2002;63:83-90.
12. Hackstein H, Thomson AW. Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004;4:24-34.
13. Adorini L, Giarratana N, Penna G. Pharmacological induction oftolerogenic den-dritic cells and regulatory T cells. Semin Immunol 2004;16:127-134.
14. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
15. Steinbrink K, Wolfl M, Jonuleit H, et al. Induction oftolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-4780.
16. Takayama T, Nishioka Y, Lu L, et al. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activ-ity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998;66:1567-1574.
17. Steinbrink K, Graulich E, Kubsch S, et al. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002;99:2468-2476.
18. Faunce DE, Terajewicz A, Stein-Streilein J. Cutting edge: In vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing ex-perimental autoimmune encephalomyelitis. J Immunol 2004;172:1991-1995.
19. Luo X, Tarbell KV, Yang H, et al. Dendritic cells with TGF-beta1 differentiate naive CD4+CD25-T cells into islet-protective Foxp3+ regulatory T cells. Proc NatlAcad Sci USA 2007;104:2821-2826.
20. Carbonneil C, Saidi H, Donkova-Petrini V, Weiss L. Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: Modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells. Int Immunol 2004;16:1037-1052.
21. Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells sup-press experimental autoimmune thyroiditis by activation ofthyroglobulin-specific CD4+CD25+ T cells. J Immunol 2005;174:7433-7439.
22. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, et al. Vasoactive intestinal pep-tide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc NatlAcad Sci USA 2005;102:13562-13567.
23. Della Bella S, Nicola S, Timofeeva I, et al. Are interleukin-16 and thrombopoietin newtools forthe invitro generationofdendritic cells? Blood 2004;104:4020-4028.
24. Mennechet FJ, Uze G. Interferon-lambda-treated dendritic cells specifically in-duce proliferation ofFOXP3-expressing suppressor T cells. Blood 2006;107:4417-4423.
25. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
26. Banchereau J, Briere F, Caux C, et al. Immunobiology ofdendritic cells. Annu Rev Immunol 2000;18:767-811.
27. Cella M, Salio M, Sakakibara Y, et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999;189:821-829.
28. Fritz JH, Girardin SE, Fitting C, et al. Synergistic stimulation of human mono-cytes and dendritic cells by Toll-like receptor 4 and NOD1-and NOD2-activating agonists. Eur J Immunol 2005;35:2459-2470.
29. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production ofhigh levels ofinterleukin-12 and enhances T cell stim-ulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-752.
30. Tak PP, Firestein GS. NF-kappaB: A key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
31. Yao J, Mackman N, Edgington TS, Fan ST. Lipopolysaccharide induction of the tu-mor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem 1997;272:17795-17801.
32. Napolitani G, Bortoletto N, Racioppi L, et al. Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur J Immunol 2003;33:2832-2841.
33. Piemonti L, Monti P, Allavena P, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999;162:6473-6481.
34. Piemonti L, Monti P, Sironi M, et al. Vitamin D3 affects differentiation, mat-uration, and function of human monocyte-derived dendritic cells. J Immunol 2000;164:4443-4451.
35. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS, Jr. Role oftranscriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorti-coids. Science 1995;270:283-286.
36. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-290.
37. Scheinman RI, Gualberto A, Jewell CM, et al. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-953.
38. De Bosscher K, Vanden Berghe W, Vermeulen L, et al. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 2000;97:3919-3924.
39. Berer A, Stockl J, Majdic O, et al. 1,25-Dihydroxyvitamin D(3) inhibits den-dritic cell differentiation and maturation in vitro. Exp Hematol 2000;28: 575-583.
40. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitaminD3 inhibits differentiation, mat-uration, activation, and survival ofdendritic cells leadingto impaired alloreactive T cell activation. J Immunol 2000;164:2405-2411.
41. Cohen N, Mouly E, Hamdi H, et al. GILZ expression in human dendritic cells redirects their maturation and prevents antigen-specific T lymphocyte response. Blood 2006;107:2037-2044.
42. Dong X, Lutz W, Schroeder TM, et al. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci USA 2005;102:16007-16012.
43. Szeto FL, Sun J, Kong J, et al. Involvement of the vitamin D receptor in the regulation of NF-kappaB activity in fibroblasts. J Steroid Biochem Mol Biol 2007;103:563-566.
44. Yang J, Bernier SM, Ichim TE, et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc Biol 2003;74:438-447.
45. Woltman AM, de Fijter JW, Kamerling SW, et al. The effect of calcineurin in-hibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol 2000;30:1807-1812.
46. Tajima K, Amakawa R, Ito T, et al. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 2003;108: 321-328.
47. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocy-tosis and mannose receptor-mediated endocytosis by bone marrow-derived den-dritic cells. Blood 2002;100:1084-1087.
48. Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostim-ulatory capacity and cytokine production of human myeloid dendritic cells. J In-vestig Med 2001;49:442-449.
49. Shimizu K, Fujii S, Fujimoto K, et al. Tacrolimus (FK506) treatment of CD34 +hematopoietic progenitor cells promote the development of dendritic cells that drive CD4+ T cells toward Th2 responses. J Leukoc Biol 2000;68:633-640.
50. Woltman AM, de Fijter JW, Kamerling SW, et al. Rapamycin induces apopto-sis in monocyte-and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001;98:174-180.
51. Monti P, Mercalli A, Leone BE, et al. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003;75:137-145.
52. Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003;101:4457-4463.
53. Woltman AM, Van Der Kooij SW, Coffer PJ, et al. Rapamycin specifically inter-feres with GM-CSF signaling in human dendritic cells, leading to apoptosis via increasedp27KIP1 expression. Blood 2003;101:1439-1445.
54. Hackstein H, Morelli AE, Larregina AT, et al. Aspirin inhibits in vitro matura-tion and in vivo immunostimulatory function ofmurine myeloid dendritic cells. J Immunol 2001;166:7053-7062.
55. Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the matu-ration and function ofmurine dendritic cells. J Immunol 2000;165:2374-2381.
56. ThompsonAG, Thomas R. Induction ofimmune tolerance by dendritic cells: Impli-cations for preventative and therapeutic immunotherapy of autoimmune disease. Immunol Cell Biol 2002;80:509-519.
57. Nencioni A, Grunebach F, Zobywlaski A, et al. Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol 2002;169:1228-1235.
58. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005;51:85-94.
59. Michalik L, Auwerx J, Berger JP, et al. International Union ofPharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006;58:726-741.
60. Lovett-Racke AE, Hussain RZ, Northrop S, et al. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 2004;172:5790-5798.
61. Lee KS, Park SJ, Kim SR, et al. Modulation of airway remodeling and air-way inflammation by peroxisome proliferator-activated receptor gamma in a murine model oftoluene diisocyanate-induced asthma. J Immunol 2006;177:5248-5257.
62. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006;533:101-109.
63. Shiojiri T, Wada K, Nakajima A, et al. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheuma-toid arthritis mice. Eur J Pharmacol 2002;448:231-238.
64. Kielian T, Drew PD. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res 2003;71:315-325.
65. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflamma-tory mediators in human T lymphocytes: Implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002;90:703-710.
66. Gosset P, Charbonnier AS, Delerive P, et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived den-dritic cells. Eur J Immunol 2001;31:2857-2865.
67. Appel S, Mirakaj V, Bringmann A, et al. PPAR-gamma agonists inhibit toll-like receptor-mediated activation ofdendritic cells via the MAP kinase and NF-kappaB pathways. Blood 2005;106:3888-3894.
68. Klotz L, Dani I, Edenhofer F, et al. Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy. J Immunol 2007;178:2122-2131.
69. Wei-guo Z, Hui Y, Shan L, et al. PPAR-gamma agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-kappaB pathways. Immunol Cell Biol 2010;88:305-312.
70. Harizi H, Grosset C, Gualde N. Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol 2003;73:756-763.
71. Winn HR, Rubio R, Berne RM. Brain adenosine concentration during hypoxia in rats. Am J Physiol 1981;241:H235-H242.
72. Van Belle H, Goossens F, Wynants J. Formation and release ofpurine catabolites during hypoperfusion, anoxia, and ischemia. Am J Physiol 1987;252:H886-H893.
73. Marquardt DL, Gruber HE, Wasserman SI. Adenosine release from stimulated mast cells. Proc NatlAcad Sci USA 1984;81:6192-6196.
74. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994;76:5-13.
75. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation andexpansion. Blood 1997;90:1600-1610.
76. Eigler A, Greten TF, Sinha B, et al. Endogenous adenosine curtails lipopolysaccharide-stimulated tumor necrosis factor synthesis. Scand J Immunol 1997;45:132-139.
77. Hoskin DW, Reynolds T, Blay J. Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumors. Int J Cancer 1994;59: 854-855.
78. la Sala A, Ferrari D, Corinti S, et al. Extracellular ATP induces a distorted mat-uration of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol 2001;166:1611-1617.
79. Yang D, Zhang Y, Nguyen HG, et al. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 2006;116: 1913-1923.
80. Thiel M, Caldwell CC, Sitkovsky MV. The critical role ofadenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect 2003;5:515-526.
81. Heystek HC, Thierry AC, Soulard P, Moulon C. Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. Int Immunol 2003;15:827-835.
82. Wilson JM, Ross WG, Agbai ON, et al. The A2B adenosine receptor im-pairs the maturation and immunogenicity of dendritic cells. J Immunol 2009;182:4616-4623.
83. Tournier JN, Quesnel-Hellmann A, Mathieu J, et al. Anthrax edema toxin coop-erates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J Immunol 2005;174:4934-4941.
84. Bagley KC, Abdelwahab SF, Tuskan RG, et al. Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived den-dritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway J Leukoc Biol 2002;72:962-969.
85. Lavelle EC, McNeela E, Armstrong ME, et al. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J Immunol 2003;171:2384-2392.
86. Hickey FB, Brereton CF, Mills KH. Adenylate cycalse toxin of Bordetella per-tussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells. J Leukoc Biol 2008;84:234-243.
87. Li K, Anderson KJ, Peng Q, et al. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood 2008;112:5084-5094.
88. Tao XL, Sun Y, Dong Y, et al. A prospective, controlled, double-blind, cross-over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis. Chin MedJ(Engl) 1989;102:327-332.
89. Li YT, Qin YZ, Qu Y, Gong JZ. Hydroxypiperaquine phosphate in treating chloro-quine resistant falciparum malaria. Chin Med J (Engl) 1981;94:303-304.
90. Qin WZ, Zhu GD, Yang SM, et al. Clinical observations on Tripterygium wil-fordii in treatment of 26 cases of discoid lupus erythematosus. J Tradit Chin Med 1983;3:131-132.
91. Gu WZ, Brandwein SR. Inhibition of type II collagen-induced arthritis in rats by triptolide. Int J Immunopharmacol 1998;20:389-400.
92. Wu Y, Wang Y, Zhong C, et al. The suppressive effect of triptolide on experi-mental autoimmune uveoretinitis by down-regulating Th1-type response. Int Im-munopharmacol 2003;3:1457-1465.
93. Kupchan SM, Court WA, Dailey RG, Jr., et al. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 1972;94:7194-7195.
94. Su D, Song Y, Li R. [Comparative clinical study of rheumatoid arthritis treated by triptolide and an ethyl acetate extract of Tripterygium wilfordii]. Zhong Xi Yi Jie He Za Zhi 1990;10:31, 144-146.
95. Chen X, Murakami T, Oppenheim JJ, Howard OM. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor ofdendritic-cell maturation and trafficking. Blood 2005;106:2409-2416.
96. Zhu KJ, Shen QY, Cheng H, et al. Triptolide affects the differentiation, matura-tion and function of human dendritic cells. Int Immunopharmacol 2005;5:1415-1426.
97. Liu Q, Chen T, Chen H, et al. Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activa-tion. Biochem Biophys Res Commun 2004;319:980-986.
98. Liu Q, Chen T, Chen G, et al. Immunosuppressant triptolide inhibits den-dritic cell-mediated chemoattraction of neutrophils and T cells through inhibiting Stat3 phosphorylation and NF-kappaB activation. Biochem Biophys Res Commun 2006;345:1122-1130.
99. Kim GY, Kim KH, Lee SH, et al. Curcumin inhibits immunostimulatory function ofdendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 2005;174:8116-8124.
100. Kim HK, Lee JJ, Lee JS, et al. Rosmarinic acid down-regulates the LPS-induced production of monocyte chemoattractant protein-1 (MCP-1) and macrophage in-flammatory protein-1alpha (MIP-1alpha) via the MAPK pathway in bone-marrow derived dendritic cells. Mol Cells 2008;26:583-589.
101. Chen Y, Yang C, Jin N, et al. Sinomenine promotes differentiation but impedes maturation and co-stimulatory molecule expression of human monocyte-derived dendritic cells. Int Immunopharmacol 2007;7:1102-1110.
102. Toth BI, Benko S, Szollosi AG, et al. Transient receptor potential vanilloid-1 sig-naling inhibits differentiation and activation of human dendritic cells. FEBS Lett 2009;583:1619-1624.
103. Rios JL. Effects of triterpenes on the immune system. J Ethnopharmacol 2010;128:1-14.
104. Yoneyama S, Kawai K, Tsuno NH, et al. Epigallocatechin gallate affects hu-man dendritic cell differentiation and maturation. J Allergy Clin Immunol 2008;121:209-214.
105. Arrighi JF, Rebsamen M, Rousset F, et al. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 2001;166:3837-3845.
106. Ardeshna KM, Pizzey AR, Devereux S, et al. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 2000;96:1039-1046.
107. Hehner SP, Heinrich M, Bork PM, et al. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 1998;273:1288-1297.
108. Hehner SP, Hofmann TG, Droge W, Schmitz ML. The antiinflammatory sesquiter-pene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 1999;163:5617-5623.
109. Kang BY, Chung SW, Kim TS. Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by parthenolide, a predominant sesquiterpene lactone in Tanacetum parthenium: Involvement of nuclear factor-kappaB. Immunol Lett 2001;77:159-163.
110. Takaesu G, Kishida S, Hiyama A, et al. TAB2, a novel adaptor protein, medi-ates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway Mol Cell 2000;5:649-658.
111. Kopp E, Medzhitov R, Carothers J, et al. ECSIT is an evolutionarily con-served intermediate in the Toll/IL-1 signal transduction pathway Genes Dev 1999;13:2059-2071.
112. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, et al. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999;398:252-256.
113. Wallach D, Varfolomeev EE, Malinin NL, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-367.
114. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mam-malian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997;275:90-94.
115. Nishitoh H, Saitoh M, Mochida Y, et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 1998;2:389-395.
116. Uchi H, Arrighi JF, Aubry JP, et al. The sesquiterpene lactone parthenolide in-hibits LPS-but not TNF-alpha-induced maturation of human monocyte-derived dendritic cells by inhibition of the p38 mitogen-activated protein kinase pathway J Allergy Clin Immunol 2002;110:269-276.
117. Chen XL, Grey JY, Thomas S, et al. Sphingosine kinase-1 mediates TNF-alpha-induced MCP-1 gene expression in endothelial cells: Upregulation by oscillatory flow. Am J Physiol Heart Circ Physiol 2004;287:H1452-H1458.
118. Wu W, Mosteller RD, Broek D. Sphingosine kinase protects lipopolysaccharide-activated macrophages from apoptosis. Mol Cell Biol 2004;24:7359-7369.
119. Jin Y, Knudsen E, Wang L, et al. Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood 2003;101:4909-4915.
120. Spiegel S. Sphingosine 1-phosphate: a prototype of a new class of second messen-gers. J Leukoc Biol 1999;65:341-344.
121. Ott VL, Cambier JC. Introduction: Multifacetedrolesoflipids andtheircatabolites in immune cell signaling. Semin Immunol 2002;14:1-6.
122. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation ofinhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-5969.
123. Jung ID, Lee JS, Kim YJ, et al. Sphingosine kinase inhibitor suppresses dendritic cell migration by regulating chemokine receptor expression and impairing p38 mitogen-activatedproteinkinase. Immunology 2007;121:533-544.
124. Giordano D, Magaletti DM, Clark EA. Nitric oxide and cGMP protein kinase (cGK) regulate dendritic-cell migration toward the lymph-node-directing chemokine CCL19. Blood 2006;107:1537-1545.
125. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 reg-ulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50.
126. Chang CC, Ciubotariu R, Manavalan JS, et al. Tolerization of dendritic cells by T(S) cells: The crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002;3:237-243.
127. Svajger U, Obermajer N, Jeras M. Dendritic cells treated with resveratrol dur-ing differentiation from monocytes gain substantial tolerogenic properties upon activation. Immunology 2010;129:525-535.
128. Penna G, Roncari A, Amuchastegui S, et al. Expression of the inhibitory re-ceptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005;106:3490-3497.
129. Fedoric B, Krishnan R. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent ofFoxP3 induction. Immunol Lett 2008;120:49-56.
130. Buckland M, Jago CB, Fazekasova H, et al. Aspirin-treated human DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Am J Transplant 2006;6:2046-2059.
131. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999;189:1363-1372.
132. Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000;164:3596-3599.
133. Fallarino F, Vacca C, Orabona C, et al. Functional expression ofindoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol 2002;14:65-68.
134. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5:2516-2522.
135. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004;172:4100-4110.
136. Grohmann U, Fallarino F, Bianchi R, et al. IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol 2001;167:708-714.
137. Grohmann U, Fallarino F, Silla S, et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol 2001;166:277-283.
138. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophancatabolism. Science 1998;281:1191-1193.
139. MellorAL, Sivakumar J, ChandlerP, et al. PreventionofTcell- drivencomplement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001;2:64-68.
140. Sakurai K, Zou JP, Tschetter JR, et al. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;129:186-196.
141. Belladonna ML, Grohmann U, Guidetti P, et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence offunctional IDO. J Immunol 2006;177:130-137.
142. Vogel CF, Goth SR, Dong B, et al. Aryl hydrocarbon receptor signaling medi-ates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 2008;375:331-335.
143. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007;396: 203-213.
144. Jonsson ME, Franks DG, Woodin BR, et al. The tryptophan photoproduct 6-formylindolo[3,2-b]carbazole (FICZ) binds multiple AHRs and induces multi-ple CYP1 genes via AHR2 in zebrafish. Chem Biol Interact 2009;181:447-454.
145. Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008;453:65-71.
146. Skov S, Rieneck K, Bovin LF, et al. Histone deacetylase inhibitors: A new class of immunosuppressors targeting a novel signal pathway essential for CD154 expres-sion. Blood 2003;101:1430-1438.
147. Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates in-doleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008;118:2562-2573.
148. Liu K, Victora GD, Schwickert TA, et al. In vivo analysis ofdendritic cell develop-ment andhomeostasis. Science 2009;324:392-397.
149. Fogg DK, Sibon C, Miled C, et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 2006;311:83-87.
150. Varol C, Landsman L, Fogg DK, et al. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med 2007;204:171-180.
151. Naik SH, Sathe P, Park HY, et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol 2007;8:1217-1226.
152. Onai N, Obata-Onai A, Schmid MA, et al. Identification of clonogenic com-mon Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol 2007;8:1207-1216.
153. Jakubzick C, Bogunovic M, Bonito AJ, et al. Lymph-migrating, tissue-derived dendritic cells are minor constituents within steady-state lymph nodes. J Exp Med 2008;205:2839-2850.
154. Randolph GJ, Beaulieu S, Lebecque S, et al. Differentiation ofmonocytes into den-dritic cells in a model oftransendothelial trafficking. Science 1998;282:480-483.
155. Kirsch BM, Zeyda M, Stuhlmeier K, et al. The active metabolite ofleflunomide, A77 1726, interferes with dendritic cell function. Arthritis Res Ther 2005;7:R694-R703.
156. BreedveldFC, DayerJM. Leflunomide: Mode ofactioninthetreatmentofrheuma- toid arthritis. Ann Rheum Dis 2000;59:841-849.
157. Migita K, Miyashita T, Ishibashi H, et al. Suppressive effect ofleflunomide metabo-lite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheuma-toid synovial fibroblasts. Clin Exp Immunol 2004;137:612-616.
158. Xie J, Qian J, Yang J, et al. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival ofmonocyte-derived immature dendritic cells. Exp Hematol 2005;33:564-572.
159. Richter K, Muschler P, Hainzl O, Buchner J. Coordinated ATP hydrolysis by the Hsp90 dimer. J Biol Chem 2001;276:33689-33696.
160. Crouvezier S, Powell B, Keir D, Yaqoob P. The effects ofphenolic components of tea on the production of pro-and anti-inflammatory cytokines by human leukocytes invitro. Cytokine 2001;13:280-286.
161. Al-Hanbali M, Ali D, Bustami M, et al. Epicatechin suppresses IL-6, IL-8 and enhances IL-10 production with NF-kappaB nuclear translocation in whole blood stimulated system. Neuro Endocrinol Lett 2009;30:131-138.
162. Yang F, Oz HS, Barve S, et al. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 2001;60:528-533.
163. Hashimoto F, Ono M, Masuoka C, et al. Evaluation of the anti-oxidative effect (in vitro) of tea polyphenols. Biosci Biotechnol Biochem 2003;67:396-401.
164. Bors W, Saran M. Radical scavenging by flavonoid antioxidants. Free Radic Res Commun 1987;2:289-294.
165. Mukhtar H, Katiyar SK, Agarwal R. Green tea and skin\Anticarcinogenic effects. J Invest Dermatol 1994;102:3-7.
166. Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev Res (Phila Pa) 2009;2:514-517.
167. Tachibana H. Molecular basis for cancer chemoprevention by green tea polyphenol EGCG. Forum Nutr 2009;61:156-169.
168. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003;102:4090-4098.
169. Rutella S, Bonanno G, Procoli A, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 2006;108:218-227.
170. Eljaafari A, Li YP, Miossec P. IFN-gamma, as secreted during an alloresponse, induces differentiation of monocytes into tolerogenic dendritic cells, resulting in FoxP3+ regulatory T cell promotion. J Immunol 2009;183:2932-2945.
171. Adhami VM, Afaq F, Ahmad N. Suppression ofultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia 2003;5:74-82.
172. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: A treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
173. Athar M, Back JH, Kopelovich L, et al. Multiple molecular targets ofresveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 2009;486:95-102.
174. Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009;11:2851-2897.
175. Stewart JR, Ward NE, Ioannides CG, O'Brian CA. Resveratrol preferen-tially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 1999;38:13244-13251.
176. Frojdo S, Cozzone D, Vidal H, Pirola L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem J 2007;406:511-518.
177. Venkatachalam K, Mummidi S, Cortez DM, et al. Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2008;294:H2078-H2087.
178. Youn HS, Lee JY, Fitzgerald KA, et al. Specific inhibition of MyD88-independent signaling pathways ofTLR3 and TLR4 by resveratrol: Molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 2005;175:3339-3346.
179. Borrok MJ, Kiessling LL. Non-carbohydrate inhibitors of the lectin DC-SIGN. J Am Chem Soc 2007;129:12780-12785.
180. Geijtenbeek TB, van Vliet SJ, Engering A, et al. Self-and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 2004;22:33-54.
181. Sauder DN. Immunomodulatory and pharmacologic properties ofimiquimod. J Am Acad Dermatol 2000;43:S6-S11.
182. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995;58: 365-372.
183. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cy-tokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002;218:74-86.
184. Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: rela-tion to central nervous system antitumor immunity J Immunol 2006;176:157-164.
185. Zhu KJ, Cen JP, Lou JX, et al. Imiquimod inhibits the differentiation but enhances the maturation of human monocyte-derived dendritic cells. Int Immunopharmacol 2009;9:412-417.
186. Yang F, Ji G, Chen YB, Wang WZ. [The effects of sinomenine on the expresssion ofICAM-1 and IL-2 during the rejection of rat cardiac allograft]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007;23:240-241.
187. Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based im-munotherapy for autoimmunity. Int Rev Immunol 2010;29:156-183.
188. van Duivenvoorde LM, Louis-Plence P, Apparailly F, et al. Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis Rheum 2004;50:3354-3364.
189. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238.
190. Popov I, Li M, Zheng X, et al. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: A novel tolerogenic vaccine. Arthritis Res Ther 2006;8:R141.
191. Martin E, Capini C, Duggan E, et al. Antigen-specific suppression ofestablished arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum 2007;56:2255-2266.
192. Haase C, Yu L, Eisenbarth G, Markholst H. Antigen-dependent immunother-apy ofnon-obese diabetic mice with immature dendritic cells. Clin Exp Immunol 2010;160:331-339.
193. Harnaha J, Machen J, Wright M, et al. Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes 2006;55:158-170.
194. Ma L, Qian S, Liang X, et al. Prevention ofdiabetes in NOD mice by administration ofdendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes 2003;52:1976-1985.
195. Machen J, Harnaha J, Lakomy R, et al. Antisense oligonucleotides down-regulating co-stimulation confer diabetes-preventive properties to nonobese di-abetic mouse dendritic cells. J Immunol 2004;173:4331-4341.
196. Phillips B, Giannoukakis N, Trucco M. Dendritic cell-based therapy in Type 1 diabetes mellitus. Expert Rev Clin Immunol 2009;5:325-339.